Your browser doesn't support javascript.
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.
Wang, Zijun; Schmidt, Fabian; Weisblum, Yiska; Muecksch, Frauke; Barnes, Christopher O; Finkin, Shlomo; Schaefer-Babajew, Dennis; Cipolla, Melissa; Gaebler, Christian; Lieberman, Jenna A; Oliveira, Thiago Y; Yang, Zhi; Abernathy, Morgan E; Huey-Tubman, Kathryn E; Hurley, Arlene; Turroja, Martina; West, Kamille A; Gordon, Kristie; Millard, Katrina G; Ramos, Victor; Da Silva, Justin; Xu, Jianliang; Colbert, Robert A; Patel, Roshni; Dizon, Juan; Unson-O'Brien, Cecille; Shimeliovich, Irina; Gazumyan, Anna; Caskey, Marina; Bjorkman, Pamela J; Casellas, Rafael; Hatziioannou, Theodora; Bieniasz, Paul D; Nussenzweig, Michel C.
  • Wang Z; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Schmidt F; Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
  • Weisblum Y; Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
  • Muecksch F; Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
  • Barnes CO; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
  • Finkin S; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Schaefer-Babajew D; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Cipolla M; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Gaebler C; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Lieberman JA; Lymphocyte Nuclear Biology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Oliveira TY; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Yang Z; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
  • Abernathy ME; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
  • Huey-Tubman KE; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
  • Hurley A; Hospital Program Direction, The Rockefeller University, New York, NY, USA.
  • Turroja M; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • West KA; Department of Transfusion Medicine, National Institutes of Health Clinical Center, Bethesda, MD, USA.
  • Gordon K; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Millard KG; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Ramos V; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Da Silva J; Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
  • Xu J; Lymphocyte Nuclear Biology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Colbert RA; Pediatric Translational Research Branch and Office of the Clinical Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Patel R; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Dizon J; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Unson-O'Brien C; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Shimeliovich I; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Gazumyan A; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Caskey M; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Bjorkman PJ; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA. bjorkman@caltech.edu.
  • Casellas R; Lymphocyte Nuclear Biology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA. rafael.casellas@nih.gov.
  • Hatziioannou T; The NIH Regulome Project, National Institutes of Health, Bethesda, MD, USA. rafael.casellas@nih.gov.
  • Bieniasz PD; Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA. thatziio@rockefeller.edu.
  • Nussenzweig MC; Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA. pbieniasz@rockefeller.edu.
Nature ; 592(7855): 616-622, 2021 04.
Article in English | MEDLINE | ID: covidwho-1075232
ABSTRACT
Here we report on the antibody and memorycell responses of a cohort of 20 volunteers who received the Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccine against SARS-CoV-21-4. Eight weeks after the second injection of vaccine, volunteers showed high levels of IgM and IgG anti-SARS-CoV-2 spike protein (S) and receptor-binding-domain (RBD) binding titre. Moreover, the plasma neutralizing activity and relative numbers of RBD-specific memorycells of vaccinated volunteers were equivalent to those of individuals who had recovered from natural infection5,6. However, activity against SARS-CoV-2 variants that encode E484K-, N501Y- or K417N/E484K/N501-mutant S was reduced by a small-but significant-margin. The monoclonal antibodies elicited by the vaccines potently neutralize SARS-CoV-2, and target a number of different RBD epitopes in common with monoclonal antibodies isolated from infected donors5-8. However, neutralization by 14 of the 17 most-potent monoclonal antibodies that we tested was reduced or abolished by the K417N, E484K or N501Y mutation. Notably, these mutations were selected when we cultured recombinant vesicular stomatitis virus expressing SARS-CoV-2 S in the presence of the monoclonal antibodies elicited by the vaccines. Together, these results suggest that the monoclonal antibodies in clinical use should be tested against newly arising variants, and that mRNA vaccines may need to be updated periodically to avoid a potential loss of clinical efficacy.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines, Synthetic / Spike Glycoprotein, Coronavirus / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines / Variants Language: English Journal: Nature Year: 2021 Document Type: Article Affiliation country: S41586-021-03324-6

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines, Synthetic / Spike Glycoprotein, Coronavirus / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines / Variants Language: English Journal: Nature Year: 2021 Document Type: Article Affiliation country: S41586-021-03324-6